Sharat Singh

Mirati Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

36h-index6.0kcitations241works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(94), Microscopic Colitis(67), Monoclonal and Polyclonal Antibodies Research(38), Immunodeficiency and Autoimmune Disorders(31), HER2/EGFR in Cancer Research(21)

Publications240 total

Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis
Journal of Crohn s and Colitis·2025· 2 citedOpen Access
Anti-TNF nonresponse in ulcerative colitis: correcting for mucosal drug exposure reveals distinct cytokine profiles
Journal of Crohn s and Colitis·2025· 1 cited
Evaluation of a Novel Smart Capsule Bacterial Detection System Device for Diagnosis of Small Intestinal Bacterial Overgrowth
Neurogastroenterology & Motility·2024· 7 cited
Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer
UNC Libraries·2024Open Access
Su1778 RESULTS OF HUMAN DEVICE FUNCTION STUDIES FOR THE NAVICAP™ TARGETED ORAL DELIVERY PLATFORM IN HEALTHY VOLUNTEERS AND PATIENTS WITH UC
Gastroenterology·2024· 1 cited
80-LB: Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist Delivered through the BIOJET Oral Biotherapeutic Delivery Platform in Porcine Model
Diabetes·2023
Table S1 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
Data from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
Figures S1-S10 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
Supplementary Table 1 from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
Figures S1-S10 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
Data from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
Table S1 from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
POTENTIAL EFFECTS OF FOOD ON A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER A THERAPEUTIC COMPOUND IN THE COLON
Gastroenterology·2023Open Access
Data from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
Supplementary Materials from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
Data from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
DEVELOPMENT OF A NOVEL DRUG DELIVERY SYSTEM (DDS) TO DELIVER DRUGS DIRECTLY TO THE COLONIC MUCOSA TO IMPROVE EFFICACY AND REDUCE SYSTEMIC EXPOSURE FOR THE TREATMENT OF ULCERATIVE COLITIS (UC)
Gastroenterology·2023Open Access
Supplementary Materials from HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
2023Open Access
Supplementary Table 1 from An <i>In vivo</i> Platform for Translational Drug Development in Pancreatic Cancer
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Scott Hauenstein(14), Séverine Vermeire(9), Fred Princen(9), Ann Gils(7), Steven Lockton(7), Niels Vande Casteele(6), Linda Ohrmund(6), Paul Rutgeerts(5), Anjali Jain(5), Emil Chuang(5), Marc Ferrante(5), José Baselga(4), S. Lockton(4), Andrés Yarur(4), Daniel A. Sussman(4), Jamie S. Barkin(4), Amar R. Deshpande(4), María T. Abreu(4), Goverdhan Mehta(4), Gert Van Assche(4)